TKTL1 Knockdown Impairs Hypoxia-Induced Glucose-6-phosphate Dehydrogenase and Glyceraldehyde-3-phosphate Dehydrogenase Overexpression.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
25 Mar 2022
Historique:
received: 01 02 2022
revised: 22 03 2022
accepted: 23 03 2022
entrez: 12 4 2022
pubmed: 13 4 2022
medline: 14 4 2022
Statut: epublish

Résumé

Increased expression of transketolase (TKT) and its isoform transketolase-like-1 (TKTL1) has been related to the malignant leukemia phenotype through promoting an increase in the non-oxidative branch of the pentose phosphate pathway (PPP). Recently, it has also been described that TKTL1 can have a role in survival under hypoxic conditions and in the acquisition of radio resistance. However, TKTL1's role in triggering metabolic reprogramming under hypoxia in leukemia cells has never been characterized. Using THP-1 AML cells, and by combining metabolomics and transcriptomics techniques, we characterized the impact of TKTL1 knockdown on the metabolic reprogramming triggered by hypoxia. Results demonstrated that TKTL1 knockdown results in a decrease in TKT, glucose-6-phosphate dehydrogenase (G6PD) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) activities and impairs the hypoxia-induced overexpression of G6PD and GAPDH, all having significant impacts on the redox capacity of NADPH- and NADH-related cells. Moreover, TKTL1 knockdown impedes hypoxia-induced transcription of genes encoding key enzymes and transporters involved in glucose, PPP and amino acid metabolism, rendering cells unable to switch to enhanced glycolysis under hypoxia. Altogether, our results show that TKTL1 plays a key role in the metabolic adaptation to hypoxia in THP-1 AML cells through modulation of G6PD and GAPDH activities, both regulating glucose/glutamine consumption and the transcriptomic overexpression of key players of PPP, glucose and amino acids metabolism.

Identifiants

pubmed: 35408935
pii: ijms23073574
doi: 10.3390/ijms23073574
pmc: PMC8999113
pii:
doi:

Substances chimiques

G6PD protein, human EC 1.1.1.49
Glucosephosphate Dehydrogenase EC 1.1.1.49
Glyceraldehyde-3-Phosphate Dehydrogenases EC 1.2.1.-
GAPDH protein, human EC 1.2.1.12
Glyceraldehyde-3-Phosphate Dehydrogenase (Phosphorylating) EC 1.2.1.12
TKTL1 protein, human EC 2.2.1.1
Transketolase EC 2.2.1.1
Glucose IY9XDZ35W2

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : European Commission
ID : HaemMetabolome H2020-MSCA-ITN-2015-675790
Organisme : Ministry of Economy, Industry and Competitiveness
ID : SAF2017-89673-R
Organisme : Ministry of Economy, Industry and Competitiveness
ID : PID2020-115051RB-I00
Organisme : Agency for Administration of University and Research
ID : 2017SGR1033
Organisme : Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas
ID : CB17/04/00023

Références

Bioinformatics. 2015 Jan 15;31(2):166-9
pubmed: 25260700
Cells. 2019 Sep 08;8(9):
pubmed: 31500396
Int J Cancer. 1980 Aug;26(2):171-6
pubmed: 6970727
EMBO Rep. 2016 Jun;17(6):811-22
pubmed: 27113762
Biomed Pharmacother. 2015 Aug;74:71-6
pubmed: 26349965
Cancers (Basel). 2020 Nov 19;12(11):
pubmed: 33228196
Elife. 2019 Dec 16;8:
pubmed: 31841108
ACS Chem Biol. 2011 Feb 18;6(2):169-75
pubmed: 20886892
Pathol Res Pract. 2012 Apr 15;208(4):203-9
pubmed: 22445516
Biochim Biophys Acta. 2011 Jun;1807(6):746-54
pubmed: 21185256
Science. 2015 Jan 23;347(6220):1260419
pubmed: 25613900
Blood. 2015 Feb 26;125(9):1367-76
pubmed: 25550361
Nat Commun. 2018 Dec 21;9(1):5442
pubmed: 30575741
Blood. 2015 Apr 23;125(17):2621-9
pubmed: 25762174
BMC Cancer. 2015 Jun 10;15:2
pubmed: 26187043
Trends Biochem Sci. 2020 Mar;45(3):228-243
pubmed: 31473074
Open Life Sci. 2018 Dec 31;13:569-581
pubmed: 33817128
Oncology. 2021;99(3):177-185
pubmed: 33120381
Front Cell Dev Biol. 2021 Feb 02;9:625524
pubmed: 33604337
J Exp Bot. 2021 Oct 26;72(20):6856-6866
pubmed: 34331757
Br J Cancer. 2017 Mar 28;116(7):930-936
pubmed: 28208156
Nat Commun. 2019 Jun 7;10(1):2502
pubmed: 31175280
J Exp Clin Cancer Res. 2009 Mar 30;28:43
pubmed: 19331662
Anticancer Res. 2010 May;30(5):1653-9
pubmed: 20592357
Biochim Biophys Acta. 2016 Oct;1863(10):2531-9
pubmed: 26724577
Genome Biol. 2014;15(12):550
pubmed: 25516281
Tumour Biol. 2015 Nov;36(11):8519-29
pubmed: 26032094
Int J Cancer. 2009 Mar 15;124(6):1330-7
pubmed: 19065656
Oncol Lett. 2019 May;17(5):4213-4221
pubmed: 30944616
PLoS One. 2012;7(9):e46324
pubmed: 23050013
Nat Rev Cancer. 2021 Feb;21(2):122-137
pubmed: 33328584
Nat Cell Biol. 2018 Jul;20(7):775-781
pubmed: 29941933
Am J Cardiovasc Dis. 2016 May 18;6(2):46-54
pubmed: 27335690
Proc Natl Acad Sci U S A. 2020 Oct 20;117(42):26340-26346
pubmed: 33020282
Lancet. 2006 Nov 25;368(9550):1894-907
pubmed: 17126723
J Biol Chem. 2008 Oct 17;283(42):28106-14
pubmed: 18718909
J Biol Chem. 2006 Dec 29;281(52):39897-906
pubmed: 17079227
Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):348-355
pubmed: 27913501
Cancer Cell. 2018 Nov 12;34(5):724-740.e4
pubmed: 30423294
Am J Physiol Lung Cell Mol Physiol. 2000 Feb;278(2):L407-16
pubmed: 10666126
Genome Biol. 2010;11(10):R106
pubmed: 20979621
J Nutr. 1985 Apr;115(4):509-15
pubmed: 2858518
Eur J Biochem. 2001 Aug;268(15):4177-82
pubmed: 11488910
J Neurosci. 2018 Aug 29;38(35):7683-7700
pubmed: 30054395
Blood. 2016 May 19;127(20):2391-405
pubmed: 27069254
PLoS One. 2010 Nov 03;5(11):e13823
pubmed: 21072205
Eur J Nucl Med Mol Imaging. 2020 Apr;47(4):787-797
pubmed: 31832727
Leuk Lymphoma. 2021 Sep;62(9):2064-2078
pubmed: 33944660
Int J Hematol Oncol Stem Cell Res. 2017 Oct 1;11(4):328-339
pubmed: 29340131
Int J Mol Sci. 2018 Jul 25;19(8):
pubmed: 30044385
Biochemistry. 1992 Dec 29;31(51):12792-8
pubmed: 1463749
Cancers (Basel). 2021 Jan 23;13(3):
pubmed: 33498690
BMC Struct Biol. 2019 Jan 15;19(1):2
pubmed: 30646877
Oncotarget. 2016 Aug 9;7(32):51875-51897
pubmed: 27391434
Cancer Biol Ther. 2020 Sep 1;21(9):826-831
pubmed: 32795237
J Cancer Res Clin Oncol. 2014 Mar;140(3):411-7
pubmed: 24390277
Histol Histopathol. 2005 Oct;20(4):1327-38
pubmed: 16136514
Urol Oncol. 2018 Oct;36(10):472.e21-472.e27
pubmed: 30119993
J Exp Biol. 2003 Jun;206(Pt 12):2049-57
pubmed: 12756287
Dis Model Mech. 2011 Nov;4(6):727-32
pubmed: 22065843
Blood. 2013 Feb 28;121(9):1633-43
pubmed: 23297133
Exp Mol Med. 2020 Sep;52(9):1496-1516
pubmed: 32943735
Proc Natl Acad Sci U S A. 2015 Apr 28;112(17):E2217-24
pubmed: 25870284
Pflugers Arch. 2016 Jan;468(1):13-22
pubmed: 26490456

Auteurs

Inês Baptista (I)

Department of Biochemistry and Molecular Biomedicine, Faculty of Biology, Universitat de Barcelona (UB), 08028 Barcelona, Spain.
Institute of Biomedicine of University of Barcelona (IBUB), University of Barcelona (UB), 08028 Barcelona, Spain.
Institute of Cancer and Genomic Sciences, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK.

Effrosyni Karakitsou (E)

Department of Biochemistry and Molecular Biomedicine, Faculty of Biology, Universitat de Barcelona (UB), 08028 Barcelona, Spain.
Institute of Biomedicine of University of Barcelona (IBUB), University of Barcelona (UB), 08028 Barcelona, Spain.
Institute of Cancer and Genomic Sciences, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK.
Centre for Computational Biology, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK.

Jean-Baptiste Cazier (JB)

Institute of Cancer and Genomic Sciences, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK.
Centre for Computational Biology, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK.

Ulrich L Günther (UL)

Institute of Chemistry and Metabolomics, University of Lübeck, 23562 Lübeck, Germany.

Silvia Marin (S)

Department of Biochemistry and Molecular Biomedicine, Faculty of Biology, Universitat de Barcelona (UB), 08028 Barcelona, Spain.
Institute of Biomedicine of University of Barcelona (IBUB), University of Barcelona (UB), 08028 Barcelona, Spain.
CIBER of Hepatic and Digestive Diseases (CIBEREHD), Institute of Health Carlos III (ISCIII), 28029 Madrid, Spain.

Marta Cascante (M)

Department of Biochemistry and Molecular Biomedicine, Faculty of Biology, Universitat de Barcelona (UB), 08028 Barcelona, Spain.
Institute of Biomedicine of University of Barcelona (IBUB), University of Barcelona (UB), 08028 Barcelona, Spain.
CIBER of Hepatic and Digestive Diseases (CIBEREHD), Institute of Health Carlos III (ISCIII), 28029 Madrid, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH